Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR 461.50
-4.15 (-0.89%)
At close: Jan 20, 2026
Lincoln Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 6,322 | 6,232 | 5,805 | 5,103 | 4,721 | 4,242 | Upgrade | |
Revenue Growth (YoY) | 5.81% | 7.35% | 13.76% | 8.09% | 11.30% | 9.75% | Upgrade |
Cost of Revenue | 3,006 | 2,970 | 2,831 | 2,457 | 2,219 | 2,014 | Upgrade |
Gross Profit | 3,315 | 3,262 | 2,975 | 2,646 | 2,502 | 2,228 | Upgrade |
Selling, General & Admin | 1,232 | 1,179 | 1,074 | 981.38 | 845.1 | 756.63 | Upgrade |
Other Operating Expenses | 1,071 | 1,052 | 898.46 | 767.12 | 692 | 597.41 | Upgrade |
Operating Expenses | 2,443 | 2,364 | 2,079 | 1,840 | 1,625 | 1,430 | Upgrade |
Operating Income | 872.12 | 897.38 | 895.83 | 805.47 | 876.98 | 798.01 | Upgrade |
Interest Expense | -6.48 | -9.96 | -9.46 | -16.38 | -9.2 | -12.02 | Upgrade |
Interest & Investment Income | 73.1 | 73.1 | 70.28 | 61.71 | 50.28 | 22.65 | Upgrade |
Currency Exchange Gain (Loss) | 80.79 | 80.79 | 46.1 | 109.14 | 11.12 | 4.26 | Upgrade |
Other Non Operating Income (Expenses) | 12.3 | -8.87 | -5.19 | -3.92 | -4.6 | 1.63 | Upgrade |
EBT Excluding Unusual Items | 1,032 | 1,032 | 997.56 | 956.02 | 924.58 | 814.53 | Upgrade |
Gain (Loss) on Sale of Investments | 61.2 | 61.2 | 227.85 | 51.35 | 36.12 | 24.5 | Upgrade |
Gain (Loss) on Sale of Assets | -1.76 | -1.76 | -2.98 | -2.56 | -1.31 | -1.82 | Upgrade |
Pretax Income | 1,091 | 1,092 | 1,222 | 1,005 | 959.39 | 837.21 | Upgrade |
Income Tax Expense | 291.24 | 268.42 | 289.38 | 275.81 | 265.84 | 214.71 | Upgrade |
Earnings From Continuing Operations | 800.04 | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade |
Net Income | 800.04 | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade |
Net Income to Common | 800.04 | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade |
Net Income Growth | -17.21% | -11.74% | 27.99% | 5.11% | 11.41% | 21.02% | Upgrade |
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade |
Shares Change (YoY) | -0.01% | - | - | - | - | 0.15% | Upgrade |
EPS (Basic) | 39.94 | 41.11 | 46.58 | 36.40 | 34.63 | 31.08 | Upgrade |
EPS (Diluted) | 39.94 | 41.11 | 46.58 | 36.40 | 34.63 | 31.08 | Upgrade |
EPS Growth | -17.21% | -11.74% | 27.98% | 5.11% | 11.41% | 20.84% | Upgrade |
Free Cash Flow | 785.44 | 739.86 | 237.41 | 250.03 | 306.07 | 605.19 | Upgrade |
Free Cash Flow Per Share | 39.21 | 36.94 | 11.85 | 12.48 | 15.28 | 30.21 | Upgrade |
Dividend Per Share | 1.800 | 1.800 | 1.800 | 1.500 | 1.500 | 1.500 | Upgrade |
Dividend Growth | - | - | 20.00% | - | - | - | Upgrade |
Gross Margin | 52.44% | 52.34% | 51.24% | 51.84% | 52.99% | 52.52% | Upgrade |
Operating Margin | 13.80% | 14.40% | 15.43% | 15.78% | 18.57% | 18.81% | Upgrade |
Profit Margin | 12.65% | 13.21% | 16.07% | 14.29% | 14.69% | 14.67% | Upgrade |
Free Cash Flow Margin | 12.43% | 11.87% | 4.09% | 4.90% | 6.48% | 14.27% | Upgrade |
EBITDA | 1,006 | 1,025 | 1,001 | 895.8 | 956.29 | 872.01 | Upgrade |
EBITDA Margin | 15.92% | 16.45% | 17.24% | 17.55% | 20.26% | 20.56% | Upgrade |
D&A For EBITDA | 134.24 | 127.76 | 104.97 | 90.33 | 79.31 | 74 | Upgrade |
EBIT | 872.12 | 897.38 | 895.83 | 805.47 | 876.98 | 798.01 | Upgrade |
EBIT Margin | 13.80% | 14.40% | 15.43% | 15.78% | 18.57% | 18.81% | Upgrade |
Effective Tax Rate | 26.69% | 24.58% | 23.67% | 27.45% | 27.71% | 25.65% | Upgrade |
Revenue as Reported | 6,568 | 6,457 | 6,150 | 5,328 | 4,821 | 4,298 | Upgrade |
Advertising Expenses | - | 26.68 | 10.34 | 11.57 | 0.6 | 0.47 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.